Clinical Scorecard: Dual-Agent Eye Drop for Presbyopia
At a Glance
| Category | Detail |
|---|---|
| Condition | Presbyopia |
| Key Mechanisms | Combination of carbachol and brimonidine tartrate to improve near vision. |
| Target Population | Adults experiencing presbyopia, typically starting around age 45. |
| Care Setting | Prescribed by eye care professionals, available through e-pharmacy and retail pharmacies. |
Key Highlights
- YUVEZZI is the first dual-agent eye drop approved for presbyopia.
- Single drop, once-daily dosing improves near vision.
- Designed to meet the real-world needs of aging adults.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of presbyopia typically occurs in adults around age 45.
Management
- Prescribe YUVEZZI for improved near vision in adults with presbyopia.
Monitoring & Follow-up
- Monitor patient response to treatment and adjust as necessary.
Risks
- Evaluate for potential side effects associated with carbachol and brimonidine tartrate.
Patient & Prescribing Data
Adults with presbyopia.
YUVEZZI offers a convenient treatment option that reduces reliance on reading glasses.
Clinical Best Practices
- Educate patients on the proper use of YUVEZZI.
- Assess the patient's vision needs and lifestyle when prescribing.
Related Resources & Content
- American Optometric Association Health Policy Institute
- National Eye Institute - Presbyopia
- Global Prevalence of Presbyopia
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
